Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 5.38% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTMerck & Co., Inc.'s latest supported as-filed period reports revenue of $16.6B, 5.1% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 5.38% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 32.34% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 5.07% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 37.38% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 73.54% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 58.66% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -14.5% from the comparable as-filed period.
Inventory changed -6.0% from the comparable as-filed period.
Net income changed -130.2% from the comparable as-filed period.
Research & development changed +140.6% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
MRK · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000310158-26-000223SEC ↗4Aug 13, 2026Period Aug 12, 20260000310158-26-000221SEC ↗4Aug 12, 2026Period Aug 10, 20260000310158-26-000219SEC ↗4Aug 10, 2026Period Aug 6, 20260000310158-26-000217SEC ↗4Aug 7, 2026Period Aug 5, 20260000310158-26-000215SEC ↗4Aug 7, 2026Period Aug 5, 20260000310158-26-000214SEC ↗4Aug 7, 2026Period Aug 6, 20260000310158-26-000213SEC ↗10-QTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026Filed Aug 13, 2026 | Guindo ChirfiEVP, Access, Policy & Comms | Open Market SaleDirect | 10,000 | $135 | $1.4M | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 1.79% · OPTIONAL
Revenue changed +5.1% from the comparable as-filed period.
Selling, general & administrative changed +9.6% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000310158-26-000212